Merck & Co Inc
(FRA:6MK)
€
92.9
-0.2 (-0.21%)
Market Cap: 236.96 Bil
Enterprise Value: 261.27 Bil
PE Ratio: 21.36
PB Ratio: 5.93
GF Score: 78/100 Merck & Co Inc at JPMorgan Healthcare Conference Transcript
Jan 10, 2023 / 01:15AM GMT
Release Date Price:
€103.4
(+0.78%)
Christopher Thomas Schott
JPMorgan Chase & Co, Research Division - Senior Analyst
Good afternoon. I'm Chris Schott at JPMorgan, and it's my pleasure to be wrapping up day 1 of the JPMorgan conference with the presentation from Merck. From the company, we have the company's Chairman and CEO, Rob Davis; as well as Dean Li, who is President of Merck Research Labs. After a very successful 2022 for the company, looking forward to Rob's presentation and comments on '23 and beyond. And then after the presentation, we'll go to some fireside chat Q&A on the stage here.
So with that, I'll turn it over to Rob.
Robert M. Davis
Merck & Co., Inc. - CEO & Chairman
Thanks a lot.
Christopher Thomas Schott
JPMorgan Chase & Co, Research Division - Senior Analyst
Thanks so much.
Robert M. Davis
Merck & Co., Inc. - CEO & Chairman
Appreciate it. Thank you. Good afternoon, everybody. Obviously, we will be making forward-looking statements, and I'd
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot